SunVax mRNA Therapeutics
Biotechnology company developing mRNA therapeutics through lipid nanoparticle delivery and self-amplifying mRNA technologies. The organization focuses on delivery specificity, payload amplification, and platform integration to enable applications in immuno-oncology, vaccines, autoimmune and rare diseases. Offers research-use delivery kits and publishes technical data on platform performance.
Industries
Nr. of Employees
small (1-50)
Patents
Synthetic self-amplifying MRNA molecules with secretion antigen and immunomodulator
US-12416032-B2
View DetailsSynthetic self-amplifying mRNA molecules with secretion antigen and immunomodulator
US-12084703-B2
View Details
Synthetic self-amplifying MRNA molecules with secretion antigen and immunomodulator
US-12416032-B2
View DetailsSynthetic self-amplifying mRNA molecules with secretion antigen and immunomodulator
US-12084703-B2
View DetailsProducts
Lipid nanoparticle delivery platform (technical disclosure)
Technical disclosure and documentation describing the company's lipid nanoparticle design and formulation approaches.
Self-amplifying mRNA platform (technical disclosure)
Documentation describing self-amplifying mRNA strategies that encode replicase machinery to amplify intracellular expression.
Cascade amplification platform (published paper PDF)
Published technical paper describing cascade amplification of therapeutic payloads combining delivery, self-amplifying payloads, and amplification cascades.
LNP Technology & samRNA Platform
An innovative lipid nanoparticle (LNP) delivery technology that leverages an extensive self-amplifying mRNA (SamRNA) platform to advance mRNA medicines in oncology, vaccines, autoimmune diseases and rare diseases.
Proprietary-LNP
Proprietary lipid nanoparticle formulation platform for mRNA delivery.
CATP™
A platform combining LNP delivery, samRNA payloads, and a pseudovirus-based amplification cascade to amplify therapeutic payloads in situ and enhance immune priming.
Lipid nanoparticle delivery platform (technical disclosure)
Technical disclosure and documentation describing the company's lipid nanoparticle design and formulation approaches.
Self-amplifying mRNA platform (technical disclosure)
Documentation describing self-amplifying mRNA strategies that encode replicase machinery to amplify intracellular expression.
Cascade amplification platform (published paper PDF)
Published technical paper describing cascade amplification of therapeutic payloads combining delivery, self-amplifying payloads, and amplification cascades.
LNP Technology & samRNA Platform
An innovative lipid nanoparticle (LNP) delivery technology that leverages an extensive self-amplifying mRNA (SamRNA) platform to advance mRNA medicines in oncology, vaccines, autoimmune diseases and rare diseases.
Proprietary-LNP
Proprietary lipid nanoparticle formulation platform for mRNA delivery.
CATP™
A platform combining LNP delivery, samRNA payloads, and a pseudovirus-based amplification cascade to amplify therapeutic payloads in situ and enhance immune priming.
Services
Research-use kits designed to enable targeted mRNA delivery to specific cell types for preclinical experiments.
Research-use kits designed to direct mRNA therapeutics to specific tissues (examples cited: liver, lymphatic system).
Research-use kits designed to enable targeted mRNA delivery to specific cell types for preclinical experiments.
Research-use kits designed to direct mRNA therapeutics to specific tissues (examples cited: liver, lymphatic system).
Expertise Areas
- mRNA therapeutics
- Lipid nanoparticle delivery systems
- Targeted delivery (cell- and tissue-specific)
- Self-amplifying mRNA platforms
Key Technologies
- Lipid nanoparticles (LNPs)
- Self-amplifying mRNA
- Ionizable lipid libraries
- High-throughput screening
News & Updates
Published article/paper describing a cascade amplification approach combining delivery systems and self-amplifying mRNA to increase in situ expression.
Published article/paper describing a cascade amplification approach combining delivery systems and self-amplifying mRNA to increase in situ expression.